Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifampridine phosphate versus placebo in MuSK-positive myasthenia gravis
2017-004018-25Phase 3Completed
- Sponsor
- Catalyst Pharmaceuticals
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in myasthenia gravis (MG) comparing Amifampridine phosphate with Placebo (2 arms). Primary endpoint: Change in MG-ADL score. Started Jan 2021; status: completed.
02
Drugs
amifampridine
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2017-004018-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004018-25.